From scientific complexity to market execution.

A 2026 Science study uses CRISPR TAPIR to increase rRNA transcription and asks whether translation capacity itself can shape stem cell fate, linking ribosome biology with regeneration, ribosomopathies, and cancer.

Four ISSCR 2026 keynotes point to one conclusion: gene delivery is the real bottleneck in cell and gene therapy. What it means for CMC, CDMOs, and capital.

Executive Summary If you only have three minutes to read this article, here are five key takeaways: Aging is increasingly viewed as a biological process that can potentially be modified, rather than an inevitable consequence of time. The discovery of the Yamanaka Factors revolutionized modern biology by demonstrating that cell identity is reversible, leading to the development of induced pluripotent stem cells (iPSCs). Today, the most exciting direction in aging research is P

Executive Summary If you only have three minutes to read this article, I hope you'll remember these six things first. The real challenge of Gene Therapy is not just finding the therapeutic gene, but how to safely and effectively deliver the gene into the right cells. AAV (Adeno-associated virus) is one of the most mature in vivo gene delivery platforms currently available. Researchers remove most of the virus's genes, retaining only the structures needed for delivery, and the